

## Appendix 5.1: Statement of Work

**Proposal Number:** MTEC-20-09-COVID19-064

**Organization:** VxBiosciences Inc.

**Title:** Rapid Development of Transmissible, Self-deploying Therapeutic Interfering Particles (TIPs) to Reduce Population-Level COVID-19 Transmission

**ACURO and/or HRPO approval needed:** Yes

**Electronic Grant System # (EGS):** MT20009.064

VxBiosciences, Inc will provide all FDA communications and documents related to this award for review if requested by SOTR, ORA and ORP.

### INTRODUCTION/BACKGROUND

(b) (4) interactions regarding (b) (4) : (b) (4)  
(b) (4)

(b) (4) (4)

(b) (4) (4)

(b) (4) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

To address these challenges, the (b) (4) ) developed (b) (4) (b) (4) . The technology, termed (b) (4) Most (b) (4) (b) (4) (Fig. 1). (b) (4) is partnering with VxBiosciences Inc. to (b) (4)

The (b) (4) (b) (4)  
1. (b) (4)

**SCOPE/PROJECT OBJECTIVE**

*Project objectives/goals:* Engineer (b) (4) test (b) (4) and (b) (4)

*Hypothesis:* (b) (4)

*Study design:* VxBiosciences Inc. will (b) (4) (b) (4)

*Major Milestones:* (b) (4)

*Deliverables:* (i) (b) (4) (ii) (b) (4) (iii) (b) (4)

**REQUIREMENTS**

The objective/goals (b) (4)

The three major phases of the efforts in this proposal are:

1) (b) (4)

The Tasks are as follows:

(b) (4)

Subtask 1.1: (b) (4)

Subtask 1.2: (b) (4)

Task 2: (b) (4)

Subtask 2.1: (b) (4)

Subtask 2.2: (b) (4)

Subtask 2.3: (b) (4)

Task 3: (b) (4)

Task 4: (b) (4)

Subtask 4.1: (b) (4)

Subtask 4.2: (b) (4)

Subtask 4.3 (b) (4)

Task 5: (b) (4)

Task 6: (b) (4)

Subtask 6.1: (b) (4)

(b) (4)

Subtask 6.2: (b) (4)

Subtask 6.3: (b) (4)

Task 7: (b) (4)

Subtask 7.1: (b) (4)

Subtask 7.2: (b) (4)

Task 8: (b) (4)

Subtask 8.1: (b) (4)

(b) (4)  
(D) (4)

(b) (4)

Subtask 8.2: (b) (4)

(b) (4)

Study Site: (b) (4)

will be the clinical trial site to conduct

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

## Deliverables

Task 1 deliverables

(b) (4)

Task 2 deliverables: (b) (4)

Task 3 deliverables: (b) (4)

Task 4 deliverables: (b) (4)

Task 5 deliverables: (b) (4)

Task 6 deliverables: (b) (4)

Task 7 deliverables: (b) (4)

Task 8 deliverables: (b) (4)

## Milestone Payment Schedule

MTEC Milestone Number	Task Number	Significant Events / Accomplishments	Due Date	Government Funds	Site	Total Funding
1	1	Project Kickoff	6/1/2020	(b) (4)	VxB/(b) (4)	(b) (4)
2	1	(b) (4)	6/1/2020	(b) (4)	VxB/(b) (4)	(b) (4)
3	2	(b) (4)	6/1/2020	(b) (4)	VxB	(b) (4)
4	2	(b) (4)	6/1/2020	(b) (4)	VxB/(b) (4)	(b) (4)
5	2	(b) (4)	6/14/2020	\$0	VxB/(b) (4)	\$0
6	2	(b) (4)	6/21/2020	(b) (4)	VxB/(b) (4)	(b) (4)
7	3	(b) (4)	6/22/2020	(b) (4)	VxB	(b) (4)
8	4	(b) (4)	7/2/2020	(b) (4)	VxB/GLD	(b) (4)
9	4	(b) (4)	7/15/2020	(b) (4)	GLD	(b) (4)
10	4	(b) (4)	7/15/2020	(b) (4)	VxB	(b) (4)
11	N/A	(b) (4)	7/25/2020	\$0	VxB	\$0
12	5	(b) (4)	8/14/2020	(b) (4)	(b) (4)	(b) (4)
13	N/A	(b) (4)	8/14/2020	\$0	VxB/(b) (4)	\$0
14	6	(b) (4)	9/1/2020	(b) (4)	VxB/(b) (4)	(b) (4)
15	7	(b) (4)	9/15/2020	(b) (4)	VxB	(b) (4)
16	6	(b) (4)	9/15/2020	(b) (4)	(b) (4)	(b) (4)
17	8	(b) (4)	10/1/2020	(b) (4)	VxB	(b) (4)
18	1	(b) (4)	10/1/2020	(b) (4)	VxB/(b) (4)	(b) (4)
19	6	(b) (4)	10/15/2020	(b) (4)	VxB	(b) (4)
20	8	Quarterly Report 2 (July-September, Technical and Business Reports)	10/25/2020	\$0	VxB	\$0
21	8	(b) (4)	11/1/2020	(b) (4)	(b) (4)	(b) (4)



22	8	(b) (4)	11/15/2020	(b) (4)	(b) (4)	(b) (4)
23	8	(b) (4)	12/2/2020	(b) (4)	VxB	(b) (4)
24	8	(b) (4)	12/16/2020	\$0	(b) (4)	\$0
25	8	(b) (4)	1/1/2021	(b) (4)	VxB	(b) (4)
26	8	(b) (4)	1/15/2021	\$0	(b) (4)	\$0
27	8	(b) (4)	1/15/2021	\$0	(b) (4)	\$0
28	N/A	Quarterly Report 3 (October-December, Technical and Business Reports)	1/24/2021	\$0	VxB	\$0
29	N/A	Final Reports (Business and Technical)	1/25/2021	\$0	VxB	\$0
		Total		\$5,926,890.00	(b) (4)	\$5,926,890.00